The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback